MedTrace Logo

Antiretroviral Therapy for Acute HIV Infection

NCT03877536 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2019-04-26

No results posted yet for this study

Summary

This study will evaluate the virologic effect, safety and tolerability of Genvoya® in adults during early acute HIV infection.

Conditions

  • HIV Infections

Interventions

DRUG

Genvoya 150Mg-150Mg-200Mg-10Mg Tablet

Participants will receive 1 tablet per day throughout study duration (96 weeks).

Sponsors & Collaborators

  • Gilead Sciences

    collaborator INDUSTRY

  • Henry M. Jackson Foundation for the Advancement of Military Medicine

    lead OTHER

Principal Investigators

  • Christina Polyak, MD, MPH · Henry M. Jackson Foundation in support of MHRP

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-17
Primary Completion
2023-09-14
Completion
2025-09-14

Countries

  • Uganda

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03877536 on ClinicalTrials.gov